Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects Bifendate and talinolol in healthy subjects

Xenobiotica

Volumn 39, Issue 11, 2009, Pages 844-849

  Zeng, Y ^a   He, F Y ^a   He, Y J ^a   Dai, L L ^a   Fan, L ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bifendate; Pharmacokinetics; Talinolol

Indexed keywords

ANTIVIRUS AGENT; BIFENDATE; TALINOLOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; BIPHENYL COMPOUNDS; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; MALE; PROPANOLAMINES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 70350289673     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498250903111870     Document Type: Article

References (40)

1. Abdel-Hameid NA. (2007). Protective role of dimethyl diphenyl bicarboxylate (DDB) against erythromycin induced hepatotoxicity in male rats. Toxicol In Vitro 21:618-625
2. Abdel-salam OM, Sleem AA, Morsy FA. (2007). Effect of biphenyldimethyl- dicarboxylate administrate alone or combined with silymarin in the CCL4 model of liver fibrosis in rats. Sci World J 7:1242-1255
3. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. (2005). Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol 70:949-958
4. Anglicheau D, Legendre C, Beaune P, Thervet E. (2007). Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8:835-849
5. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. (2005). P-glycoprotein and surfactant: effect on intestinal talinolol absorption. Clin Pharmacol Ther 77:24-32.
6. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R, Picard V. (2004). MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients. Transplantation 78:21-25
7. Campeanu A. (2001). The Cardiac Insufficiency Talinolol Study (CITAS) study design. Eur J Heart Fail 3:377-380
8. Cascorbi I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457-473
9. Cui S, Wang M, Fan G. (2002). Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study. Zhonghua Yi Xue Za Zhi 82:538-540
10. Ekins S, Mirny L, Schuetz EG. (2002). A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRα, and LXRβ. Pharm Res 19:1788-1800
11. Endres CJ, Hsiao P, Chung FS, Unadkat JD. (2006). The role of transporters in drug interactions. Eur J Pharm Sci 27:501-517
12. Fan L, Mao XQ, Tao GY, Jiang F, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Huang YF, Wang D, Zhou HH. (2009). Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 3:249-254
13. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. (2004). Carbamazepin regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192-200.
14. Gramatté T, Oertel R, Terhaag B, Kirch W. (1996). Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59:541-549
15. Guan LP, Nan JX, Jin XJ, Jin QH, Kwak KC, Chai KY, Quan ZS. (2005). Protective effects of chalcone derivatives for acute liver injury in mice. Arch Pharm Res 28:81-86
16. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. (2007). The role of nuclear receptors in pharmacokinetic drug-drug interaction in oncology. Cancer Treat Rev 33:369-380
17. Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH. (2006). Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 33:1093-1098
18. Huang SM, Lesko LJ. (2004). Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 44:559-569
19. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670
20. Ito K, Kusuhara H, Sugiyama Y. (1999). Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 16:225-231
21. Krishnamurthy P, Xie T, Schuetz JD. (2007). The role of tansporters in cellular heme and porphyrin homeostasis. Pharmacol Ther 114:345-358
22. Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. (2006). Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 316:1369-1377
23. Oertel R, Richter K, Trausch B, Berndt A, Gramatté T, Kirch W. (1994). Elucidation of the structure of talinolol metabolites in man: determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in plasma. J Chromatogr B Biomed Appl 660:353-363
24. Owen A, Chandler B, Back DJ, Khoo SH. (2004). Expression of pregnane- X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir Ther 9:819-821
25. Pan SY, Yang R, Dong H, Yu ZL, Ko KM. (2006). Bifendate treatmeng attenuates hepatic steatosis in cholesterol/bile salt and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol 552:170-175
26. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678
27. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. (2005). Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 77:291-301.
28. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, Langguth P, Tamai I. (2009). Concentration-dependent effect of naringin on intestinal absorption of β1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 26:560-567
29. Sourgens H, Schmidt J, Derendorf H. (2003). Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters: results from the TALIP study. Int J Clin Pharmacol Ther 41:22-29
30. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
31. Staudinger JL, Madan A, Carol KM, Parkinson A. (2003). Regulation of drug transporter gene expression by nuclear receptors. Drug Metab Dispos 31:523-527
32. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. (2005). CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42:420-430
33. Wang XD, Li JL, Su QB, Deng XY, Lu Y, Chen J, Zhang JX, Zhao LZ, Zuo Z, Chan E, Chen E, Chowbay B, Xue CC, Huang M, Zhou FF. (2007). A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab 8:778-786
34. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, Von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. (2000). Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355
35. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of taliniolol enatiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522
36. Yang CQ, Park KO, Namgung HU, Jing ZJ, Sun PY, Shin WG. (2006). Effect of bifendate on pharmacokinetics of cyclosporine A in Beagle dogs. Chin J Hosp Pharm 26:565-567
37. Yao GB. (2000). Treatment of chronic hepatitis B in China. J Gastroenterol Hepatol 15:61-66
38. Yu AR, Wu XC, Li Q, Xin HW, Zhu M. (2004). Effects of bifendate on the blood concentration and hepatic toxicity of cyclosporine A in renal transplanted recipients. Chin J Clin Pharmacol Ther 9:548-550
39. Zeng Y, He YJ, He FY, Fan L, Zhou HH. (2009). The effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4 18B genotype in healthy subjects. Acta Pharmacol Sin 30:478-484
40. Zhu M, Yeung RY, Lin KF, Li RC. (2000). Improvement of phase I drug metabolism with Schisandra chinensis against CCL4 hepatotoxicity in a rat model. Planta Med 66:521-525